ENTRADA THERAPEUTICS, INC. TRDA 深 滬
已收盤 09-20 16:00:00 美东时间
14.68
-0.320
-2.13%
華盛通- 最 高15.085
- 今 開14.84
- 成交量 43.40万股
- 最 低 14.55
- 昨 收 15.00
- 總市值 4.88亿
- 52周最高 18.17
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 10.7501
- 委 比 -80.03%
- 總股本 3327.15万
- 歷史最高 36.85
- 量 比 2.94
- 振 幅 3.57%
- 歷史最低 5.12
- 每 手 1
- 風險率 1.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dyne stock tumbles 31% amid drug updates, management changes
Shares of Dyne Therapeutics (NASDAQ:DYN) fell 31% Tuesday after the company released new data from a clinical trial called DELIVER for its drug DYNE-251 in the treatment of Duchenne muscular dystrophy...
09-04 04:48
Oppenheimer Reiterates Outperform on Entrada Therapeutics, Maintains $25 Price Target
Oppenheimer analyst Francois Brisebois reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Outperform and maintains $25 price target.
08-26 22:54
PepGen stock tumbles 25% following release of DMD drug data
PepGen (NASDAQ:PEPG) stock plunged 25% in post-market trading Tuesday after the company released data for its drug PGN-EDO51 in the treatment of Duchenne muscular dystrophy, or DMD. PepGen reported da...
07-31 07:37
Entrada Therapeutics announces $100M registered direct offering
Entrada Therapeutics (NASDAQ:TRDA) entered into a securities purchase agreement for the purchase of about 3.4M shares of common stock and pre-funded warrants to purchase up to 3.4M shares of common st...
06-24 20:59
Entrada Therapeutics’ Promising Phase 1 DMD Drug Trial Results
Entrada Therapeutics Inc (TRDA) has provided an announcement. Entrada Therapeut...
06-24 19:01
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 2.9x Entrada Thera...
06-20 18:03
PTC Therapeutics rallies 18% on EU authorization update for Translarna
PTC Therapeutics (NASDAQ:PTCT) stock rallied 18% early Monday after the company announced the European Commission is allowing its Duchenne muscular dystrophy therapy Translarna to remain on the market...
05-20 21:58
HHS panel to vote in Nov. on DMD screening for newborns
An advisory committee of the U.S. Department of Health and Human Services is expected to vote this fall on whether to recommend newborns be screened for Duchenne muscular dystrophy, or DMD. The Adviso...
05-10 06:44
Entrada Therapeutics(TRDA.US)：2024年Q1财报实现营收5912万美元，前值为2526万美元，预期值为1498万美元；每股收益为0.68美元，前值为-0.21美元，预期值为-0.59美元。
Entrada Therapeutics(TRDA.US)：2024年Q1财报实现营收5912万美元，前值为2526万美元，预期值为1498万美元；每股收益为...
05-07 21:31
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise Therapeutics (NASDAQ:EWTX) has received orphan drug designation from EU regulators for its drug candidate sevasemten in the treatment of Becker muscular dystrophy and Duchenne muscular dystro...
04-23 22:29
